AUPH

Aurinia Pharmaceuticals Inc

Halal Rating :
Comfortable
Last Price $9.00 Last updated:
Market Cap $973.77m
7D Change -5.76%
1 Year Change -3.43%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange NASDAQ
Next Earnings Date Oct. 31, 2024

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies to treat patients with serious autoimmune diseases. Their primary product is LUPKYNIS™ (voclosporin), an oral therapy for adult patients with active lupus nephritis (LN), which was approved by the FDA in January 2021.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $67.77m $57.23m - $1.21m 0.00% 2.11%
June 30, 2024 $57.19m $59.9m - $1.2m 0.00% 2.00%
March 31, 2024 $50.3m $64.84m - $1.28m 0.00% 1.98%

Company Impact

Help us evaluate Aurinia Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates